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T Oligo-Primed Polymerase Chain 
Reaction (TOP-PCR): A Robust 
Method for the Amplification of 
Minute DNA Fragments in Body 
Fluids
Yu-Shin Nai1,*, Tzu-Han Chen2,*, Yu-Feng Huang2, Mohit K. Midha2,3, Hsin-Chieh Shiau2,  
Chen-Yang Shen4, Chien-Jen Chen2, Alice L. Yu5,6 & Kuo Ping Chiu2,3,7
Body fluid DNA sequencing is a powerful noninvasive approach for the diagnosis of genetic defects, 
infectious agents and diseases. The success relies on the quantity and quality of the DNA samples. 
However, numerous clinical samples are either at low quantity or of poor quality due to various reasons. 
To overcome these problems, we have developed T oligo-primed polymerase chain reaction (TOP-
PCR) for full-length nonselective amplification of minute quantity of DNA fragments. TOP-PCR adopts 
homogeneous “half adaptor” (HA), generated by annealing P oligo (carrying a phosphate group at the 
5′ end) and T oligo (carrying a T-tail at the 3′ end), for efficient ligation to target DNA and subsequent 
PCR amplification primed by the T oligo alone. Using DNA samples from body fluids, we demonstrate 
that TOP-PCR recovers minute DNA fragments and maintains the DNA size profile, while enhancing the 
major molecular populations. Our results also showed that TOP-PCR is a superior method for detecting 
apoptosis and outperforms the method adopted by Illumina for DNA amplification.
Conventional Polymerase chain reaction (PCR) utilizes paired primers to define the boundaries of the target 
region and to prime DNA synthesis. Although PCR using paired-primers conveys evident advantages, the strat-
egy has an intrinsic disadvantage as far as full-length amplification of linear DNA is concerned. Based on the 
approach, it is essential for the two termini of target DNA fragment to ligate to two different adaptors, so to per-
mit the binding of two different PCR primers, each complementary to a specific site in the adaptor, for full-length 
amplification of the target DNA. Since every terminus has an equal chance to ligate to either adaptor, half of the 
DNA fragments are expected to ligate to only one type of adaptor, resulting in a 50% loss of the target sequence 
information. This strategy was carried over to SOLiDTM NGS protocol which amplifies DNA fragments on mag-
netic beads for next-generation sequencing. The outcome was not satisfactory due to significant loss of sequence 
information and inevitable requirement of large amount of DNA input.
This issue was addressed by elegant designs using forked/Y adaptor (Illumina, US 20100273662 A1) and loop 
adaptor (NEB, US 20120244525 A1, WO 2012012037 A1) for Illumina next-generation sequencing. However, 
the procedures remain tedious and NGS-oriented commercialization has made these strategies cost-ineffective. 
Furthermore, the ligation and amplification efficiencies also need to be further improved for the amplification 
of low abundance or low copy number DNA molecules. This is particularly important because large amounts of 
clinical samples are examined on daily basis and significant portion of those are either of low quantity and/or low 
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quality due to various reasons, including paraffin-embedding, long or improper storage, or at small volume or 
low concentration. As such, an efficient and nonselective method for full-length DNA amplification is desired.
Here, we present a robust but cost-effective single PCR primer-based full-length DNA amplification strategy, 
called T oligo-primed polymerase chain reaction (TOP-PCR), designed for efficient nonselective amplification 
of minute linear DNA fragments. Concordant with modern NGS molecular cloning strategies, which normally 
add an extra ‘A’ to the 3′ termini of the target DNA, we adopt a homogeneous double-stranded half adaptor (HA) 
which is formed by annealing ‘P oligo’ and ‘T oligo’ at room temperature. P oligo carries a phosphate group 
(required by ligase enzyme when later ligating HA to target DNA) at the 5′ end, while T oligo carries an extra T at 
the 3′ end for sticky-end ligation to the target DNA fragments. Originally the HA structure was designed for mul-
tiplex barcoded Paired-End Ditag (mbPED) sequencing library construction (US 8481699 and US 8829172). This 
design prevents adaptor self-ligation and allows us to maximize the ligation efficiency to an unprecedented level. 
Besides the protruding T-tail in one of the 3′ ends, there is another gcgc-tail at the other 3′ end. With a kinase treat 
followed by a ligation reaction, the extra gcgc short stretch would promote another sticky-end ligation to circular-
ize the molecule for MmeI digestion, which would in turn generate paired-end ditags for genome-wide analysis 
of gene expression and regulation. Here, without the second ligation, we employed the HA strategy for efficient 
amplification of low abundance DNA fragments in body fluids. TOP-PCR aims to amplify, in full-length, trace 
amounts of linear DNA which may be present in body fluids, so that the amplified DNA fragments can be used 
either directly for diagnosis without DNA sequencing, or, alternatively, subjected to next-generation sequencing 
using customer primer or primers provided by the sequencer manufacturer.
Body fluids such as blood plasma, saliva, urine, vaginal discharge and semen, all of which may contain trace 
amounts of cell-free circulating DNA (cfDNA), are increasingly recognized as important liquid biopsies for 
non-invasive diagnostics of infectious agents, genetic defects and various diseases, including cancer1. Plasma 
cfDNA fragments derive from both mitochondrial DNA (mtDNA) and nuclear DNA released from either apopto-
sis or necrosis of both normal and diseased cells. Sometimes, it may also carry DNA from pathogenic microbes2–4. 
The concentration of plasma cfDNA has been known to be higher in cancer patients and also increases along with 
cancer progression - with a mean value of ~13 ng per ml of blood for normal individuals and ~180 ng per ml of 
blood for some metastatic cancer patients2, and the majority are small linear DNA fragments of a few hundred 
base pairs in size and with significant variation in concentration among cancer patients. Since prolonged storage 
and repetitive freeze-thaw cycles of whole plasma can cause substantial degradation of plasma DNA5,6, we first 
tested the efficiency of TOP-PCR with plasma DNA samples, which had been stored under prolonged or unfa-
vorable conditions or isolated with inefficient method, to rescue the sequence information.
Similar to blood plasma, saliva and urine are among the most accessible body fluids. Saliva consists of a large 
spectrum of informative materials, including DNA, mRNA, and proteins of immunological, toxicological, hor-
monal and therapeutic value7,8. Applications of salivary fluid cover not only the genomics (including cancer 
genomics), transcriptomic and proteomics of the individual, but also the microbiota in the oral cavity. Reports 
have demonstrated the feasibility of using saliva in oral cancer diagnosis9, and the study of EGFR mutation for 
lung cancer patients10. Urine has also been reported to be useful for the study of cancer, such as colorectal and 
prostate cancers11,12, and the BRAF V600e mutations in Erdheim-Chester syndrome13. The cell-free DNA frag-
ments in urine are known to be between 150–250 bp in size14,15. However, high false negative rate was reported 
due to limited volume or lack of advanced technology16.
To date, most reports are associated with diseases17. Here, we demonstrate the robustness and, in some cases, 
the essentiality, of TOP-PCR to facilitate the DNA quantity and quality assessment, as well as to improve sequence 
data analysis for healthy and diseased body fluid cfDNA samples. Our results also suggest that TOP-PCR can 
significantly enhance the completeness and the sensitivity of next-generation sequencing.
Results
T oligo-primed polymerase chain reaction (TOP-PCR). The HA consists of a double-stranded back-
bone of 10 bp in length, plus a ‘T’ tail on one side and a ‘gcgc’ tail on the other (Fig. 1). Ligation of HA to both 
termini of the target DNA fragment defines the basic template structure for TOP-PCR amplification. This design 
ensures an unprecedented ligation efficiency for a strong potential to amplify low abundance and low copy num-
ber DNA fragments in the body fluids.
Amplification of homogeneous DNA fragments. To learn the basic behavior of TOP-PCR before we 
practically apply the technology in biological samples, we first characterized TOP-PCR with 166 bp TBC1D1 
DNA fragments made of a uniform sequence and then with PhiX DNA sample, which is composed of diverse 
sequences/lengths and used by Illumina as a sequencing control.
With a total length of 166 bp, the TBC1D1 DNA fragment was designed to mimic the mono-nucleosomal 
DNA fragments. As expected, addition of two HAs resulted in a distinct increase in size and TOP-PCR was able 
to well maintain its size profile (Fig. 2a). Due to the imprecision of the Fragment Analyzer, the original fragment 
is shown in the figure as the peak of 173 bp, while the amplified fragment is shown as the peak of 192 bp (188 bp, 
or 166 + 22, is expected). Such bias in size estimation is common for such types of devices and will be shown in all 
related figures throughout the report. PhiX DNA sample contains DNA fragments of variable sequences and sizes. 
TOP-PCR amplified all DNA species (Fig. 2b), including DNA of the major peak together with those of either 
smaller or larger sizes. A distinct peak shift was also observed.
TOP-PCR amplification of plasma cfDNA. We then characterized TOP-PCR using samples isolated from 
the plasmas of a cancer patient and healthy individuals, as well as saliva and urine samples from healthy individ-
uals. The plasma DNA samples were prepared and each amplified by TOP-PCR. Again, results clearly demon-
strated that TOP-PCR could maintain the profiles (Fig. 3). Back in 2001, Jahr, S. et al. demonstrated that, together 
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3Scientific RepoRts | 7:40767 | DOI: 10.1038/srep40767
with large DNA fragments which may be generated from necrosis, plasma samples of cancer patients carry DNA 
fragments of various nucleosomal sizes and these DNA fragments are potentially resulted from apoptosis of 
both healthy and diseased cells2. We have noticed that, besides the mono-nucleosomal fragments, TOP-PCR also 
emphasized, at least, the di-nucleosomal (Fig. 3a–d) and, in some cases, tri-nucleosomal (Fig. 3c,d) and above 
(Fig. 3d). The underlying reason remains unclear. However, since these pools may comprise DNA fragments 
derived from both normal and diseased cells, TOP-PCR imposes no selection upon either origin.
TOP-PCR amplification of saliva and urine cfDNA. The original human saliva DNA showed a pat-
tern very similar to that of plasma DNA, but with significantly larger amount of large-sized DNA (Fig. 4a). 
Again, TOP-PCR was able to maintain the size profile while at the same time enhancing the resolution of 
nucleosomal-sized DNA fragments. Notice that the saliva DNA contains significant amount of large-sized chro-
mosomal DNA presumably derived from necrosis, while under the current condition setting, the maximal size 
can be faithfully amplified by TOP-PCR is about 1.5 Kb, still within the size range (180–1,000 bp) for apoptotic 
DNA fragments17. If the large-sized DNA population is of interest, one can isolate it by agarose gel electrophoresis 
prior to sequencing.
Interestingly, TOP-PCR amplification of urine cfDNA revealed a distinct profile which is very different from 
that of plasma and saliva DNA samples, i.e., nucleosomal fragment DNA profile was not observed (Fig. 4b). This 
is partially due to the fact that the glomerular filtration apparatus does not permit the passage of nucleosomal 
DNA fragments to pass through.
Reproducibility of TOP-PCR. To validate the reproducibility of TOP-PCR, we isolated plasma DNA from 
a healthy male (YFH) and then repetitively preformed TOP-PCR on the same sample for a few times. Results 
indicated that TOP-PCR is highly reproducible (Fig. 5).
Comparison between TOP-PCR and Illumina’s library construction using loop adaptor. It would 
be interesting to compare TOP-PCR to Illumina’s amplification method. Here, TOP-PCR (using half adaptor) was 
compared to the Illumina PCR amplification procedure using loop adaptor, which was randomly chosen, and 
the comparison was conducted for both low (with unknown concentration) and high (20 ng) initial DNA inputs.
TOP-PCR vs. Illumina’s protocol at low DNA concentration. As shown in Fig. 6, TOP-PCR was able 
to rescue the DNA fragments from a sample with a DNA concentration far below the undetectable level by regu-
lar devices. On the other hand, Illumina’s method generated significant amount of adaptor dimers instead. PCR 
products were detected by Fragment Analyzer (FA) after 30 cycles. Here, we performed PCR for 50 cycles to 
investigate further details.
Figure 1. Procedure of T oligo-primed polymerase chain reaction (TOP-PCR). Half adaptor is generated by 
annealing P and T oligos. P oligo carries a 5′ phosphate required for ligation to target DNA fragments, while T 
oligo does not. During amplification, only the T oligo serves as the PCR primer. Number of amplification cycle 
depends on the initial concentration of the target DNA molecules and the desired final quantity.
www.nature.com/scientificreports/
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Further analysis on the sequence contents in the amplified profiles indicated that there is a dramatic difference 
between the amplified products by TOP-PCR and that by Illumina’s procedure (Table 1). Here, we isolated the 
DNA fragments by gel excision from the PCR products amplified by Illumina’s PCR and TOP-PCR methods, 
cloned the isolated DNA into pZBack vector (Tools Biotechnology), used the vectors to transform E. coli, cul-
tured 20 colonies for each, made mini-preps and sequenced the inserts with Sanger sequencing. Clones with 
empty inserts and inserts with adaptor dimers or polymers were removed. The remaining sequences were mapped 
against nr/nt database (NCBI) to identify the origins of sequences –Among the 20 pZBack clones reported 
for Illumina’s method, none mapped to the human genome. On the other hand, among the 20 pZBack clones 
reported for TOP-PCR method, 8 mapped to the human genome, indicating the superiority of TOP-PCR over 
Illumina’s method and its robustness in cloning trace DNA molecules that may be present in plasma and, in the-
ory, in other body fluids as well.
TOP-PCR vs. Illumina’s protocol using high DNA input. Comparison with high DNA input revealed 
that DNA amplification by Illumina’s method mainly focused on the mono-nucleosomal fragments, while 
TOP-PCR broadly amplified both mono- and multiple nucleosomal DNA fragments (Fig. 7). This phenomenon 
is consistently observed (also see Fig. 8 shown below). We suspect the difference may result from the following 
Figure 2. Testing of TOP-PCR on 166 bp fragment and PhiX DNA sample. (a) Size distribution of the 
original and TOP-PCR amplified 166-bp TBC1D1 DNA fragment profiled by Fragment Analyzer. (Black, 
original 166-bp fragment sample, 1 ng loaded; blue, after 20-cycle TOP PCR amplification of 1 ng of the original, 
1 ng loaded to the FA device). The peak of the original TBC1D1 fragment should be 166 bp in size, but is 
shown as a 173 bp peak due to the imprecision of the device. (b) Size distribution of the original and TOP-PCR 
amplified PhiX DNA fragments profiled by FA. (Black, original PhiX control DNA, 2.8 ng loaded; blue, after 20-
cycle TOP-PCR amplification of 1 ng of the original, 4.6 ng loaded). Size markers: 35 bp and 6000 bp peaks. Size 
of two HAs added to each DNA fragment: ~22 bp.
www.nature.com/scientificreports/
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facts: (1) HA is shorter than loop and Y adaptors; (2) HA is linear and without secondary structure, while loop 
and Y adaptors have secondary structures; and (3) TOP-PCR uses only a single oligo as PCR primer. Short and 
linear adaptor is supposed to be more accessible for target DNA fragments during ligation, while a short oligo 
is also more accessible for PCR priming. More study is needed to further understand the reasons that cause the 
difference.
Comparison of TOP-PCR to Illumina PCR using serial dilutions of a plasma cfDNA sample. To 
further understand the phenomena shown above (Figs 6 and 7), we compared these two methods using serial 
dilutions of a plasma DNA sample. Again, PCR on serial dilutions of the same plasma DNA sample isolated from 
a healthy female (BBC) revealed dramatic differences in amplification patterns between TOP-PCR and Illumina’s 
PCR method (Fig. 8). Results also indicated that Illumina’s method starts making adaptor dimers when 0.05 ng 
(50 pg) cfDNA was used as the input and became dysfunctional when input DNA is below this level. On the other 
hand, TOP-PCR maintained the full range of profile during amplification even if the input DNA reached 0.01 pg.
Comparison of our procedure using HA against Illumina’s procedure using Loop and Y adaptors. 
Both experimental procedure and adaptor play a key role in experimental efficacy. An effective experimental 
procedure should be short and comprises a minimal number of, but well optimized, experimental steps; but at 
the same time, the retention of materials, especially for low abundance and low copy number genetic materials, 
is maximized.
To further understand the differences in efficiencies of experimental procedure, adaptor ligation, and PCR 
amplification between HA, loop adaptor and Y adaptor, we conducted a number of experimental replicates using 
these adaptors together with their corresponding procedures. Results clearly demonstrated that HA procedure 
outperforms the other adaptors and their corresponding procedures (Table 2).
DNA recovery rate indicates whether DNA isolation (with magnetic beads) is required by the protocol. If 
required, 20% loss is expected, as estimated by the beads provider and experiences. As such, 100% indicates it is 
Figure 3. Size profile comparison between the original and the TOP-PCR amplified normal plasma DNA 
samples. Plasma DNA samples (1 ng each) from four normal individuals, including two males (YFH and THC, 
shown in (a,b), respectively) and two females (EJC and BBC, shown in (c,d), respectively), were each amplified 
by TOP-PCR for 20 cycles and then displayed in parallel with the originals by Fragment Analyzer. Black, 
original, 1 ng loaded; blue, after TOP-PCR, 1 ng loaded. Size markers: 35 bp and 6000 bp peaks. Size of two HAs 
added to each DNA fragment: ~22 bp.
www.nature.com/scientificreports/
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not required, while 80% indicates it is required. Ligation efficiency is an estimation based on the results shown 
in Fragment Analyzer (F.A.), which displays un-ligated, single-side ligated, and double-side ligated target DNA 
fragments in separate peak regions so that an estimation for each fraction is feasible. Previously we had tested HA 
for a number of times with ligation time ranging from 30 min to overnight. As expected, results indicated that 
both ligation efficiencies of single-sided and double-sided ligations increased along with ligation time. However, 
we have to balance between the ligation time, which should be kept within a few hours, and ligation efficiency, 
which should be maintained at a high level. Thus, we decided to choose 4 hr as the ligation time and this is most 
likely to be used in the future. Notice that the procedures used for Illumina sequencing is also much more tedious 
than our procedure.
Discussion
Initially, TOP-PCR was invented to amplify trace amounts of DNA fragments in body fluids for the study and 
diagnosis of diseases (such as cancer), bacterial/viral infections and prenatal genetic defects, using either conven-
tional diagnostic approaches or next-generation sequencing. To make it easy to use, optimization of experimental 
conditions has been conducted. The whole procedure is composed of three major steps: end repair/A-tailing, 
Figure 4. TOP-PCR amplification of saliva and urine cfDNA. (a) Size profile comparison between the 
original and TOP-PCR amplified normal saliva DNA samples. The saliva cfDNA from a healthy male individual 
(YFH) was amplified by TOP-PCR and displayed in parallel with the original. (Black, 5 ng of original; blue, 1 ng 
of TOP-PCR product). (b) Comparison between the original and TOP-PCR amplified normal urine cfDNA 
samples. Urine sample from the same healthy male (a) was tested. (Black, original urine DNA; blue, 40-cycle 
TOP-PCR amplification of 0.1 ng of the original. 5 ng each was displayed by Fragment Analyzer. Size markers: 
35 bp and 6000 bp peaks. Size of two HAs added to each DNA fragment: ~22 bp.
www.nature.com/scientificreports/
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ligation of HA to target DNA and TOP-PCR amplification. We optimized the experimental conditions for each 
step and evaluated the efficiency. Currently, no DNA purification is needed between these steps, and at the same 
time the amplification efficiency is maintained at an unprecedented level. In fact, to the best of our knowledge, 
this is the most efficient and the simplest experimental procedure of this kind.
HA is a small adaptor originally designed for cloning of barcoded paired-end ditags (bPED) and, later, for 
amplification of minute amount of cfDNA due to its superior ligation efficiency and flexible ligation time, which 
can be extended to overnight or further. The HA was so designed because each terminus of a target DNA frag-
ment can ligate only to one HA, even at excess HA concentration or elongated incubation time. Thus, after circu-
larization, only one full adaptor can be generated. These features cannot be achieved by directly using full adaptor 
for bPED cloning. We took advantage of the design and applied it to TOP-PCR for efficient DNA amplification.
Compared to HA, Y and Loop adaptors are much larger and were originally designed for sequencing, not for 
DNA amplification. Their designs are elegant for sequencing, but not for amplification. In fact, there are signifi-
cant drawbacks for adaptors and procedures used by Illumina. Besides that shown in Table 2, their protocols are 
much more tedious and require large amounts of starting material for making a sequencing library (500 pg–1 μ 
g as shown in page 4 of NEBNext UltraII DNA Library Prep Kit for Illumina, or > 100–200 ng input gDNA as 
shown in page 5 of TruSeq Nano DNA Library Prep Reference Guide). With TOP-PCR, one just needs a small 
fraction of theirs and it is thus suitable for cfDNA analysis for liquid biopsies.
In summary, our method conveys a number of advantages. Firstly, because the HA is a short homogeneous 
adaptor, it is able to ligate efficiently to the termini of DNA fragments. As such, most DNA fragments can be 
ligated and subjected to amplification. Secondly, the range of insert (target DNA) size well matches the sizes 
of cfDNA fragments in the body fluids, making it suitable for body fluid DNA amplification and sequencing. 
Thirdly, HA molecules do not self-ligate so that the concentration can be well maintained. Fourthly, TOP-PCR 
utilizes only one PCR primer and this primer was previously used to make the adaptor, making it simple and 
cost-effective. Fifthly, once amplified, DNA samples can be directly subjected to next-generation sequencing using 
customer primer. Moreover, we have also generated a protocol which allows us to perform end-repair/A-tailing, 
adaptor ligation and TOP-PCR in a single tube, without DNA purification until PCR has been conducted. This 
single-tube procedure allows us to maximize the retention of DNA molecules throughout the experiment so that 
the overall efficiency can be increased significantly.
Our results also suggest a potential application of TOP-PCR for the detection of apoptotic cell death. As 
demonstrated with plasma, saliva and urine samples, by coupling with simple devices TOP-PCR was able to 
distinguish DNA fragments of various nucleosomal sizes resulted from apoptotic cell death, making it readily dis-
tinguishable from that resulted from necrotic cell death or any other means. As such, by using TOP-PCR method 
one can bypass the conventional staining methods using multiple reagents in tedious experimental procedures.
Figure 5. Test of TOP-PCR reproducibility and cfDNA consistency. Two blood samples were separately 
collected from a healthy male (YFH) on June 30, 2015 and October 28, 2015. Plasmas were prepared right after 
the blood collections and stored at − 80 °C. Samples of cfDNA were extracted right before TOP-PCR reactions 
conducted on October 28, 2015. Blue, plasma stock prepared on June 30, 2015; red and black, plasma stock 
prepared on October 1, 2015. Size markers: 35 bp and 6000 bp peaks. Size of two HAs added to each DNA 
fragment: ~22 bp.
www.nature.com/scientificreports/
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Overall, our results demonstrate the robustness of TOP-PCR in amplifying minute DNA fragments for diag-
nosis. By coupling TOP-PCR with next-generation sequencing, we will be able to significantly improve the sensi-
tivity of sequence information in body fluids.
Methods
Preparation of 166 bp DNA fragment and PhiX DNA. To test TOP-PCR on uniform DNA fragments, 
a region of 166 bp in TBC1D1 gene ( se q.: T GA TCCAAAACAGAAAAACAGTGATAACTGTTTTGCTGAGTT
CCCAGACCCTTCCCAAGATGGAACCAATAACATTCACAGCAAGGAAACATCTGCTTTCTAACGAGGT
CTCGGTGGATTTTGGCCTGCAGCTGGTGGGCTCCCTGCCTGTGCATTCCCTGACCAC) was amplified 
with conventional PCR (primer sites underlined). The size (166 bp) was chosen to mimic the size of mono-nucle-
osomal DNA fragments previously identified in blood plasma2. The PhiX DNA is the same PhiX Control v3 DNA 
(Illumina, Inc. #FC-110-3001) used by Illumina as a control for sequencing.
Cell-free DNA isolation from blood plasma and saliva. Fresh blood samples were collected into com-
mercially available EDTA anticoagulant-treated tubes and mixed well with the anticoagulation and centrifuged 
at 3,000 × g and 4 °C for 15 min (Eppendorf, Centrifuge 5810 R). The upper light yellow phase was transferred 
into a new tube and centrifuged for another 10 min at 1,000–2,000 × g to completely remove cells and platelets. 
The plasma samples can be stored at − 80 °C. Plasma DNA was isolated by Quick-cfDNA Serum and Plasma Kit 
(Zymo Research, D4076) following the manufacturer’s instructions. Briefly, plasma samples (< 5 ml each) were 
incubated with proteinase K in digestion buffer for 30 min in a 55 °C water bath, then mixed with DNA binding 
Figure 6. Comparison of TOP-PCR with Illumina’s PCR method using low amount of DNA as the input. 
(a) One micro-liter of original ovarian cancer plasma cfDNA sample with unknown concentration. (b) Same 
DNA sample but after 50 cycles of amplification by TOP-PCR. (c) Same DNA sample but after 50 cycles of 
amplification using Illumina’s protocol. Size markers: 35 bp and 6000 bp peaks. Size of two HAs added to each 
DNA fragment: ~22 bp.
www.nature.com/scientificreports/
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buffer and loaded into the column to allow DNA to bind to the column membrane. After wash, cfDNA was eluted 
into 35 μ L ddH2O, and quantified by Qubit 2.0 Fluorometer (Invitrogen) or Fragment AnalyzerTM (AATI).
Saliva cfDNA was also isolated by using the same Quick-cfDNA Serum and Plasma Kit. About 1 mL of saliva 
was used in each preparation.
Cell-free DNA isolation from urine. Urinary cfDNA was isolated using QIAamp Circulating Nucleic Acid 
Kit (QIAGEN, 55114) following the manufacturer’s instructions. Briefly, urine samples were mixed with pro-
teinase K, buffer ACL and buffer ATL, and incubated in a 60 °C water bath for 30 min. ACB binding buffer was 
added to the mixture and the preparation was then loaded into the mini-column. Then, the liquid was flushed off 
by vacuum pump and the DNA was eluted into ddH2O and quantified by Qubit 2.0 and/or Fragment Analyzer.
Preparation of half adaptor (HA). Ligation of half adaptor to the target DNA fragments is essential for 
TOP-PCR. The HA was prepared by annealing P oligo (5′ -pGTCGGAGTCTgcgc-3′ ) and T oligo (5′ -AGA CTC 
CGA Ct-3′ ) at room temperature at 1:1 molar ratio. The P oligo carries a phosphate at the 5′ end and an additional 
‘gcgc’ sequence previously designed for another sticky-end ligation to make paired-end ditag libraries. Here the 
‘gcgc’ tail is not required for TOP-PCR, but we still keep it for potential use in the future. The T oligo has an extra 
‘T’ at the 3′ end but has no 5′ phosphate.
Ligation of HA to DNA fragments. Prior to ligation, cfDNA fragments were end-repaired and 3′ A-tailed 
using NEBNext Ultra End Repair/dA-Tailing Module (NEB, E7442S/L). The ligation mixture (30 μ L) contains 
end repaired/A-tailed cfDNA (normally ranging between 1 pg to a few ng), HA (at 50:1 ratio against cfDNA), 1X 
ligation buffer, and 1uL NEB Quick LigationTM Kit (NEB, M2200L). The reaction was incubated at 25 °C overnight 
in a thermocycler. The ligation mixture can be directly subjected to TOP-PCR amplification with or without puri-
fication. An at least 4X dilution is needed, if without purification.
TOP-PCR. TOP-PCR employs T oligo as the only PCR primer to amplify DNA fragments. The reaction mix-
ture (50 μ L) contains 10 μ L DNA template (in desired quantity), 0.64 μ M T oligo, 1.5 mM MgSO4, 0.2 mM dNTPs, 
1 X buffer, and 1unit Novagen KOD hot start DNA polymerase (EMD Millipore Co., 71086-3). The reaction 
conditions: initial denaturation at 94 °C for 3 min; (denaturation at 94 °C for 30 sec; annealing at 27 °C for 30 sec; 
elongation at 65 °C for 1 min) for 20–40 cycles; final elongation at 65 °C for 5 min; then hold at 4 °C. PCR products 
were purified with AMpure beads. When sequencing is desired, TOP-PCR products can be directly ligated to 
sequencing adaptors without fragmentation. Alternatively, the amplified products can be sonicated (e.g., by S2/
E210 Focused-ultrasonicator (Covaris) prior to ligation.
Comparison of TOP-PCR with Illumina’s method for DNA with unknown quantity. For TOP-PCR 
amplification, 1 μ L plasma DNA (with unknown quantity) from an ovarian cancer patient was end-repaired/3′ 
A-tailed following the instructions provided by the manufacturer (NEB, E7442S/L). Briefly, the reaction mixture 
(25 μ L) contained plasma DNA, 1X NEBNext end repair reaction buffer and 1 μ L NEBNext end repair enzyme 
mix, and the mixture was incubated at 25 °C for 20 min followed by 72 °C for 20 min in a thermocycler. The 
plasma DNA reparation was ligated to HA in a 30 μ L reaction mixture under the same conditions mentioned 
above. TOP-PCR reaction also followed the procedure mentioned above.
For Illumina sequencing library construction, 1 μ L plasma DNA (with unknown quantity) from an ovarian 
cancer patient was mixed in 1X end repair/A-tailing reaction buffer with end prep enzyme mix to a final volume 
of 65 μ L and then incubated at 20 °C for 30 min followed by another 30 min in a 65 °C thermocycler, as instructed 
by the manufacturer (NEBNext, E7442S/L). For adaptor ligation, the DNA preparation was mixed with 15 μ L 
Blunt/TA ligase master mix, 2.5 μ L 1:10 diluted (based on the manufacturer’s instructions) NEBNext adaptor 
PCR 
Method #/insert within pZBack flanking seq. #Seq.
Insert within 
adaptors
Illumina
2 had no reports (from Sanger sequencing)
8 with loop adaptor seq.
0 H. sapiens
2 E. coli
6 unknown
5 empty (with pZBack flanking seq. only)
5 unknown sequences
TOP-PCR
13 with HA seq.
8 H. sapiens seq.
3 E. coli seq.
1 Aeromonas veronii (a bacterium) seq.
1 unknown seq.
6 empty (with pZBack flanking seq. only)
1 unknown sequence
Table 1.  Sequence analysis of TOP-PCR and Illumina PCR products amplified from equal amount of 
ovarian cancer plasma cfDNA with undetectable quantity.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7:40767 | DOI: 10.1038/srep40767
(1.5 μ M final), and 1 μ L ligation enhancer to a final volume of 83.5 μ L. The mixture was incubated at 20 °C for 
15 min in a thermocycler. Then, 3 μ L USER™ enzyme, used to cut open the loop, was added to the ligation mix-
ture and the preparation was incubated at 37 °C for another 15 min.
Figure 7. Comparison of TOP-PCT with Illumina’s PCR method using 20 ng of DNA. (a) One nano-gram 
original plasma cfDNA sample isolated from a healthy female (BBC). (b) Same DNA sample but after 20 cycles 
of amplification using TOP-PCR. (c) Same DNA sample but after 20 cycles of amplification using Illumina’s 
protocol. Size markers: 35 bp and 6000 bp peaks. Size of two HAs added to each DNA fragment: ~22 bp.
Adaptor Input DNA (ng)
Ligation 
time
DNA recovery rate (%) Ligation efficiency (%)
DNA recovery 
rate (%)
Total efficiency (%) Ave. (%)
After  
end-repair
After 
A-tailing Un- ligated ss- ligated ds- ligated After ligation
HA
10 4 hr 100 100 13.9 20.1 66.0 80 52.8 52.5
10 4 hr 100 100 15.1 22.3 62.6 80 50.1
10 4 hr 100 100 10.5 21.3 68.2 80 54.6
Loop
100 15 min 100 100 35.0 38.6 26.4 80 21.1 22.2
100 15 min 100 100 36.4 34.6 29.0 80 23.2
Y
100 30 min 80 100 3.1 28.4 68.5 80 43.8 44.5
100 30 min 80 100 3.3 26.0 70.7 80 45.2
Table 2.  Comparison between HA, loop adaptor and Y adaptor on experimental procedure and ligation 
efficiency. 100% DNA recovery rate indicates that DNA isolation (with beads) is not required, and 80% 
indicates that it is required. Ligation efficiency is an estimation based on the results shown in Fragment 
Analyzer, which displays un-ligated, single-side ligated, and double-side ligated target DNA fragments in 
different peak regions.
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After ligation, free adaptors were removed and cleaned up by AMpure beads and DNA was collected in 23 μ L 
nuclease free water for PCR amplification. As instructed by the manufacturer, the PCR reaction mixture (50 μ L) 
contained 25 μ L NEBNext high fidelity 2X PCR master mix (final 1X), 1 μ L index primer, and 1 μ L universal PCP 
primer and ran PCR under the following conditions: initial denaturation at 98 °C for 30 sec; (denaturation at 98 °C 
for 10 sec, annealing at 65 °C for 30 sec, extension at 72 °C for 30 sec) for 15 cycles or more (when compared with 
TOP-PCR); final extension at 72 °C for 5 min, then hold at 4 °C.
Free primers were removed by AMpure beads and DNA was collected in 25 μ L nuclease free water. 2 μ L of 
collection was assessed by Fragment Analyzer, and part of the other 23 μ L was used for in cloning and transfor-
mation. 20 colonies were validated by Sanger sequencing.
Comparison of TOP-PCR with Illumina’s method for high concentration of target DNA. Normal 
female plasma DNA was first quantified by Qubit Fluorometer. We then applied 20 ng to be amplified by Illumina’s 
method for 20 cycles following the instructions provided by Illumina for input quantity ranging between 
5 ng–1 μ g. All the reagents were also provided by Illumina. In parallel, we applied another 1 ng to be amplified 
by TOP-PCR for 20 cycles. All the procedures and conditions (including end-repair/A-tailing, adaptor ligation, 
Figure 8. Comparison of TOP-PCR to Illumina’s PCR method using serial dilutions of plasma cfDNA 
sample. Serial dilutions (5 ng–0.01 pg) of a plasma cfDNA sample isolated from a healthy female (BBC) was 
prepared and the cfDNA is amplified using either Illumina’s PCR or TOP-PCR. TOP panel: profiles generated 
by Illumina’s PCR method. Lower panel: profiles generated by TOP-PCR. Notice that the RFU values are no 
longer accurate because of figure overlay. PCR cycle numbers: 30 for 5–0.5 ng; 40 for 0.05 ng–0.01 pg. Size 
markers: 1 bp and 6000 bp peaks. Size of two HAs added to each DNA fragment: ~22 bp.
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DNA purification, TOP-PCR mix preparation and conditions, and post TOP-PCR DNA purification) are exactly 
the same as described above.
Ethical Approval and Consent. All methods were performed in accordance with relevant guidelines and 
regulations.
All experimental protocols were approved by IRB on Biomedical Science Research/IRB-BM, Academia 
Sinica (AS-IRB03-105025), issued to Taiwan Biosignature Project for Breast Cancer: Investigate the Presence of 
Circulating DNA with Specific Mutations Identified by Whole Exome Sequencing of Early Onset Breast Cancer.
Informed consent was also obtained from all subjects.
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